Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction

Transplant Immunology

Volumn 23, Issue 3, 2010, Pages 117-120

  Sharma, Kavita G ^a   Radha, Raju ^a   Pao, Andy ^a   Amet, Nurmamet ^a   Baden, Lara ^a   Jordan, Stanley C ^a   Toyoda, Mieko ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cell proliferation; Intravenous immunoglobulin (IVIG); Mixed lymphocyte reaction (MLR); Mycophenolic acid (MPA); Synergistic effects

Indexed keywords

ANNEXIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; THYMIDINE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; INHIBITION KINETICS; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD19; ANTIGENS, CD3; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MYCOPHENOLIC ACID; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 77953916060     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.04.009     Document Type: Article

References (39)

1. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2-3):85.
2. Carr S.F., Papp E., Wu J.C., Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993, 268(36):27286.
3. Grinyo J.M., Gil-Vernet S., Cruzado J.M., Caldés A., Riera L, Serón D, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolatemofetil in cadaveric kidney transplantation: results after 5years. Transpl Int 2003, 16(11):820.
4. Laliberte J., Yee A., Xiong Y., Mitchell B.S. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 1998, 91(8):2896.
5. Strauss G., Osen W., Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002, 128(2):255.
6. Quemeneur L., Flacher M., Gerland L.M., Ffrench M., Revillard J.P., Bonnefoy-Berard N. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002, 169(5):2747.
7. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolatemofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353(21):2219.
8. Appel G.B., Radhakrishnan J., Ginzler E.M. Use of mycophenolatemofetil in autoimmune and renal diseases. Transplantation 2005, 80(2 Suppl):S265.
9. Nimmerjahn F., Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
10. Brandt D., Gershwin M.E. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006, 5:465-470.
11. Tha-In T., Bayry J., Metsellar H., Kaveri S., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008, 29:608-615.
12. Hartnug H.-P. Advances in the understanding of the mechanisms of action of IVIg. J Neurol 2008, 255:3-6.
13. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 2007, 19:646-651.
14. Jordan S.C., Toyoda M., Vo A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009, 88:1-6.
15. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004, 15(12):3256.
16. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 Jul 17, 359(3):242-251.
17. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, et al. Use of intravenous 324 immune globulin and rituximab for desensitization of highly HLA-sensitized 325 patients awaiting kidney transplantation. Transplantation 2010 May 15;89(9):1095-102.
18. Jordan S., Cunningham-Rundles C., McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003, 3(6):653.
19. Jordan S.C., Reinsmoen N., Peng A., Lai C.H., Cao K., Villicana R., et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010 Jan 14, Electronic publication ahead of print.
20. Toyoda M., Zhang X.M., Petrosian A., Wachs K., Moudgil A., Jordan S.C. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994, 2(4):337.
21. Toyoda M., Pao A., Petrosian A., Jordan S.C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003, 3(2):156.
22. Toyoda M., Zhang X., Petrosian A., Galera O.A., Wang S.J., Jordan S.C. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994, 14(3):178.
23. Toyoda M., Petrosyan A., Pao A., Jordan S.C. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 2004, 78(8):1134.
24. Tyan D.B., Li V.A., Czer L., Trento A., Jordan S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994, 57(4):553.
25. Jordan S.C., Quartel A.W., Czer L.S., Admon D., Chen G., Fishbein M.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998, 66(6):800.
26. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994, 121(4):259.
27. Meiser B.M., Pfeiffer M., Schmidt D., Reichenspurner H., Ueberfuhr P, Paulus D, et al. Combination therapy with tacrolimus and mycophenolatemofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999, 18(2):143.
28. Kaplan B., Meier-Kriesche H.U., Friedman G., Mulgaonkar S, Gruber S, Korecka M., et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999, 39(7):715.
29. Nakamura M., Ogawa N., Shalabi A., Maley W.R., Longo D., Burdick J.F. Positive effect on T-cell regulatory apoptosis by mycophenolatemofetil. Clin Transpl 2001, 15(Suppl 6):36.
30. Takahashi K., Reynolds M., Ogawa N., Longo D.L., Burdick J., Burton P., Chiu SH Augmentation of T-cell apoptosis by immunosuppressive agents. Clin Transpl 2004, 18(Suppl 12):72.
31. Cohn R.G., Mirkovich A., Dunlap B., Burton P., Chiu S.H., Eugui E., et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999, 68(3):411.
32. Colic M., Stojic-Vukanic Z., Pavlovic B., Jandric D., Stefanoska I. Mycophenolatemofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003, 134(1):63.
33. Chiffoleau E., Walsh P.T., Turka L. Apoptosis and transplantation tolerance. Immunol Rev 2003, 193:124.
34. Wells A.D., Li X.C., Li Y., Walsh M.C., Zheng X.X., Wu Z, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5(11):1303.
35. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999, 5(11):1298.
36. Vella A.T., Dow S., Potter T.A., Kappler J., Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A 1998, 95(7):3810.
37. Akbar A.N., Borthwick N.J., Wickremasinghe R.G., et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 1996, 26(2):294.
38. Fournel S., Genestier L., Robinet E., Flacher M., Revillard J.P. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J Immunol 1996, 157(10):4309.
39. Sadlack B., Kuhn R., Schorle H., Rajewsky K., Muller W., Horak I. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and-4. Eur J Immunol 1994, 24(1):281.